The MyPeBS clinical study: for a new breast cancer screening strategy?
October 2019 sees the Belgian launch of the MyPeBS (My Personal Breast Cancer Screening) clinical study. The objective? To evaluate a new strategy for breast cancer screening, based on the individual risk of each woman. The Jules Bordet Institute is coordinating the study partners in Belgium, that is, around 10 hospitals in the country's three regions. On a bigger scale, 26 international partners in five countries (Belgium, France, Italy, the United Kingdom and Israel) are participating in MyPeBS.
The limitations of the present screening
The breast cancer screening programme as currently organised proposes the same screening for all women aged between 50 and 69, taking just one risk factor into account: age. This when other factors mean that the cancer risk varies from one woman to another. These factors are family history, personal history, lifestyle and genetic constitution. Although screening is effective (less heavy treatment, lower mortality) it has some disadvantages: overdiagnosis (finding and treating lesions that would not have posed a problem, in the case of 1-2 lesions for every 10 detected), interval cancers (cancers not detected by screening, ¼ of cancers) and false positives (women recalled for further examinations that do not show a cancer, between 2% and 10% of women screened).
MyPeBS, for personalised breast cancer screening
Today we have validated tools to assess the individual risk in a way that is standardised, reliable and reproducible. Hence the MyPeBS (My Personal Breast Cancer Screening) clinical study, the first European randomised trial that seeks to evaluate the benefits of a personalised screening with a frequency and method adapted to the individual risk of each woman. This new screening strategy that takes into account the individual risk is designed to increase the effectiveness of organised screening while eliminating the disadvantages. This unique and ambitious project is being coordinated internationally by Unicancer (France) and conducted in five countries (Belgium, France, Italy, the United Kingdom and Israel) by 26 international partners. In Belgium about 10 screening centres, mainly hospitals, are participating in this project in the country's three regions with the Bordet Institute's Prevention and Screening Clinic charged with coordination.
The study is open to women volunteers from Monday 4 November!
The results of this study, which is set to run for seven years, will make it possible to formulate European recommendations to improve organized screening. For the study as a whole, conducted in five "recruiting" countries, 85,000 women volunteers aged between 40 and 70 and who have no previous history of breast cancer are invited to participate. In Belgium, 10,000 women are expected to volunteer.
- For further information on this study visit www.mypebs.eu and view the video below.
- If you want to participate in the study :
VIDEO : Animation video presenting the MyPeBS study
This project is being financed by the European Union's Horizon 2020 research and innovation programme in the framework of grant agreement n° 755394. In Belgium it is also being supported by the Breast Cancer Foundation.